Cloning and characterization of napsin

Details Cloning and characterization of napsin Cloning and characterization of napsin

1997-11-20

2001-05-01

Witz, Jean C. (Department: 1651)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S212000, C435S219000

Reexamination Certificate

active

06225103

ABSTRACT:

BACKGROUND OF THE INVENTION
The present invention relates to a previously unknown aspartic protease present in human liver, isolated by cloning of a gene from a human liver cDNA library.
This application claims priority to provisional patent application No. 60/031,196 entitled “Napsin, An Aspartic Protease Present in Human Liver” filed Nov. 20, 1996, by Jordan J. N. Tang, Xinli Lin, and Gerald Koelsch, and provisional patent application No. 60/046,126 entitled “Cloning and Gene Structure of Human Napsin” filed May 9, 1997, by by Jordan J. N. Tang, Xinli Lin, and Gerald Koelsch.
Members of the aspartic protease family are characterized by the presence of catalytic aspartic acid residues in their active center. There are five aspartic proteases known to be present in human body. Pepsin and gastricsin are secreted into the stomach for food digestion. Gastricsin is also present in the seminal plasma. Cathepsin D and cathepsin E are present intracellularly to carry out protein catabolism. Renin, which is present in the plasma, is the key enzyme regulating the angiotensin system and ultimately the blood pressure.
Eukaryotic, including human, aspartic proteases are homologous in protein and gene sequences, but have different amino acid and nucleotide sequences. The cDNA and genes of all five human aspartic proteases have been cloned and sequenced. They are synthesized as a single chain zymogen of about 380 residues, which are either secreted or directed to intracellular vacuoles. Upon activation by a self-catalyzed process (except prorenin), an N-terminal pro segment of about 45-residues is cleaved off to produce mature enzymes (Tang and Wong,
J. Cell. Biochem
. 33, 53-63 (1987)). In some cases, for example, with cathepsin D and renin, mature proteases are further cut into two chains. The three-dimensional structures of the aspartic proteases are very similar. Each enzyme contains two internally homologous lobes (Tang et al.,
Nature
271, 618-621 (1978)). The active-site cleft, which can accommodate eight substrate residues, and two catalytic aspartic acids, are located between the lobes.
These proteases have distinct and important physiological roles. In addition to their importance in physiological functions, these enzymes are also associated with pathological states. For example, human pepsin and gastricsin are diagnostic indicators for stomach ulcer and cancer (Samloff,
Gastroenterology
96, 586-595 (1989); Miki et al.,
Jpn. J. Cancer Res
. 84, 1086-1090 (1993)). Cathepsin D is located in the lysosome. Its main function is the catabolism of tissue proteins. Recent evidence from mice without a functional cathepsin D gene, however, indicates that this enzyme plays a role in the development of intestine in newborn animals. Cathepsin D is also associated with human breast cancer metastasis (Rochefort,
Acta Oncologica
31, 125-130 (1992)). Cathepsin E is located in the endoplasmic reticulum of some cells, such as erythrocyte and stomach mucosa cells. It has been applied in the processing of antigens in the immune cells.
Human aspartic proteases have important medical uses. The levels of the proenzymes of human pepsinogen and progastricisin present in the bloodstream and the ratio between the two levels is used in the diagnostic screening of human stomach cancer (Defize, et al.,
Cancer
59, 952-958 (1987); Miki, et al.,
Jpn. J. Cancer Res
. 84, 1086-1090 (1993)) and ulcer (Miki, et al.,
Adv. Exp. Med. Biol
. 362, 139-143 (1995)). The secretion of procathepsin D is elevated in breast cancer tissue. Thus, the level of procathepsin D in breast cancer is used for clinical prognosis (Rochefort,
Acta Oncologica
31, 125-130 (1992)). The analysis of renin in the diagnosis of hypertension is a routine clinical procedure (Brown et al.,
Handbook of Hypertension
1, 278-323 Robertson, editor (Elsevier Science Publishers, Amsterdam, 1983).
These examples establish that human aspartic proteases are related to human diseases and additional, previously unidentified aspartic proteases, are likely to have clinical applications.
It is therefore an object of the present invention to provide a previously unidentified aspartic protease.
It is a further object of the present invention to characterize and to clone the aspartic protease.
It is still another object of the present invention to identify the tissues in which the aspartic protease is expressed and applications in clinical chemistry and diagnostics.
SUMMARY OF THE INVENTION
A previously unknown aspartic protease capable of cleavage of proteins by hydrolysis, referred to herein as “napsin”, has been cloned from a human liver library. Two cDNA clones have been cloned, sequenced and expressed. These encode isozymes of the protease, referred to as “napsin A” and “napsin B”. One clone is unusual in that it does not include a stop codon but can be used to express protein. The gene has also be obtained and partially sequenced. A process for rapid purification of the enzyme using immobilized petpstatin has also been developed, and enzyme isolated from human kidney tissue. Polyclonal antibodies to the enzymes have been made which are also useful for isolation and detection of the enzyme.
Similarities to other aspartic proteases, especially cathepsin D, establish the usefulness of the enzyme in diagnostic assays as well as as a protease. Either or both the amount or type of napsin expressed in a particular tissue can be determined using labelled antibodies or nucleotide probes to the napsin.


REFERENCES:
patent: 5776759 (1998-07-01), Bandman et al.
patent: 9510630 (1995-04-01), None
Faust et al., PNAS 82: 4910-4914 (Aug. 1985).*
Adams, et al., “Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project,”Science252: 1651-1656 (1991).
Bock, “Active Site Selective Labeling of Serine Proteases with Spectroscopic Probes Using Thioester Peptide Chloromethyl Ketones: Demonstration of Thrombin Labeling Using N&agr;-[(Acetylthio)acetyl]-D-Phe-Pro-Arg-Ch2C1,”Biochemistry27:6633-6639 (1988).
Brown, et al., “The renin angiotensin system and the regulation of the circulation,”Handbook of Hypertensionvol. 1, Chapter 14, pp. 278-323 (Robertson, ed.) (Elsevier Science Publishers, Amsterdam, 1983).
Clackson, et al. “Making antibody fragments using phage display libraries,”Nature352: 624-688 (1991).
Daugherty, et al., “Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins,”Nucl. Acids Res.19(9):2471-2476 (1991).
Defize, et al., “Clinical Significance of Pepsinogen A Isozymogens, Serum Pepsinogen A and C Levels, and Serum Gastrin Levels,”Cancer59(5):952-958 (1987).
Kim, et al., “Stable propogation of cosmid sized human DNA inserts in an F factor based vector,”Nucl. Acids Res.20(5):1083-1085 (1992).
McCafferty, et al. “Phage antibodies: filamentous phage displaying antibody variable domains,”Nature348(6301):552-554.
Miki, et al., “The Clinical Applicaiton of the Serum Pepsinogen I and II levels as a Mass Screening Method for Gastric Cancer,”Adv. Exp. Med. Biol.362:139-143 (1995).
Miki, et al., “Clinical Application of Serum Pepsinogen I and II Levels for Mass Screening to Detect Gastric Cancer,”Jpn. J. Cancer Res.84(10):1086-1090 (1993).
Norman, et al., “Consensus Statement Regarding OKT3-Induced Cytokine-Release Syndrome and Human Antimouse Antibodies,”Transplant Proc.25(2)(Suppl. 1):89-93 (1993).
Rochefort, “Biological and Clinical Significance of Cathespin D in Breast Cancer,”Acta Oncologica31(2):125-130 (1992).
Samloff, “Peptic Ulcer: The Many Proteinases of Aggression,”Gastroenterology96(2)(Part 2 of 2 Parts):586-595 (1989).
Tang, et al., “Structural evidence for gene duplication in the evolution of acid proteases,”Nature271(5646):618-621 (1978).
Tang, et al., “Evolution in the Structure and Function of Aspartic Proteases,”J. Cell. Biochem.33(1):53-63 (1987).

Affiliated with

Also associated with

Rating

Cloning and characterization of napsin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cloning and characterization of napsin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cloning and characterization of napsin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2503122